The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.
 
Krisztian Homicsko
Research Funding - BMS Global; MSD; Owkin (Inst); ROCHE
 
Karim Abdelhamid
No Relationships to Disclose
 
Katerina Vervita
No Relationships to Disclose
 
Rachel Marcone
No Relationships to Disclose
 
Jesús Andrade
No Relationships to Disclose
 
Annemarie Becker-Commissaris
No Relationships to Disclose
 
Jean-Louis Pujol
No Relationships to Disclose
 
Manuel Domine
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Guardant Health; Janssen; Lilly; Merck KGaA; Novocure; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Cecile Le Pechoux
No Relationships to Disclose
 
Dirk De Ruysscher
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Olink (Inst); Philips, Inc. (Inst)
 
Roswitha Kammler
No Relationships to Disclose
 
Stephen P. Finn
Stock and Other Ownership Interests - Revolution Medicines
Consulting or Advisory Role - Amgen; Illumina; Pfizer; Roche (Inst)
Speakers' Bureau - AstraZeneca; Takeda
 
Rolf A. Stahel
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck; MSD; Novartis; Novocure; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca; BluePrint Health; Boehringer Ingelheim; GlaxoSmithKline; MSD; Roche; Sandoz
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Ipsen (Inst); Janssen (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President